Outcomes following watchful waiting for stage II–IV follicular lymphoma patients in the modern era
暂无分享,去创建一个
J. Cerhan | J. Friedberg | C. Flowers | Xiaolei Zhou | B. Link | Michael D. Taylor | M. Byrtek | K. Dawson | R. Sinha | L. Nastoupil | R. Ziemiecki
[1] J. Friedberg,et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). , 2015, Blood.
[2] J. Cerhan,et al. Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States , 2015, Leukemia & lymphoma.
[3] M. Bøgsted,et al. A population‐based study of prognosis in advanced stage follicular lymphoma managed by watch and wait , 2015, British journal of haematology.
[4] R. Advani,et al. Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Gascoyne,et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Stephens,et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. , 2014, The Lancet. Oncology.
[7] R. Houot,et al. Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma , 2013, Haematologica.
[8] R. Gascoyne,et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Cerhan,et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] T. Ittel,et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] N. Schmitz,et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.
[12] R. Marcus,et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.
[13] K. Maclennan,et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial , 2003, The Lancet.
[14] R. D'Agostino. Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .
[15] B. Nathwani,et al. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .
[16] H. Tilly,et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] E. Jaffe,et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. , 1988, Seminars in hematology.
[18] T. Lister,et al. Follicular lymphoma: prognostic factors for response and survival. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] S. Horning,et al. Female Reproductive Potential after Treatment for Hodgkin's Disease , 1981, The New England journal of medicine.
[20] S. Rosenberg,et al. No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types. , 1979, Annals of internal medicine.